We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
- Authors
Mukherjee, Debabrata; Topol, Eric J.; Bertrand, Michel E.; Kristensen, Steen D.; Herrmann, Howard C.; Neumann, Franz-Josef; Yakubov, Steven J.; Bassand, Jean-Pierre; McClure, Rick R.; Stone, Gregg W.; Ardissino, Diego; Moliterno, David J.
- Abstract
Aims Compared with placebo, abciximab has been associated with mortality reduction at late follow-up. The TARGET trial was performed to test whether tirofiban and abciximab provide similar efficacy outcomes among patients undergoing non-emergent, stent-based percutaneous coronary intervention. We report here the 1-year mortality of the study population.
- Publication
European Heart Journal, 2005, Vol 26, Issue 23, p2524
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehi459